TABLE 1.
Demographics of All Patients (n = 65)
| Characteristic | |
|---|---|
| Age at vedolizumab start (mean yrs ± SD) | 38.1 ± 16.8 |
| Female (n, %) | 39 (60) |
| BMI (mean kg/m2 ± SD) | 28.8 ± 8.1 |
| IBD type (n, %)a | |
| Crohn’s disease | 31 (48) |
| A1 | 10 (32) |
| A2 | 14 (45) |
| A3 | 7 (23) |
| L1 | 2 (6) |
| L2 | 11 (36) |
| L3 | 18 (58) |
| L4 | 0 (0) |
| B1 | 18 (58) |
| B2 | 8 (26) |
| B3 | 5 (16) |
| perianal disease | 2 (6) |
| Ulcerative colitis | 34 (52) |
| E1 | 1 (3) |
| E2 | 12 (35) |
| E3 | 21 (62) |
| Laboratory values | |
| Hemoglobin (mean ± SD) (n = 64) | 12.4 ± 1.9 |
| CRP (mean ± SD) (n = 50) | 8.0 ± 12.1 |
| Peripheral eosinophil count (mean ± SD) (n = 40) | 0.25 ± 0.19 |
| Prior medications (n, %) | |
| Any prior anti-TNF | 47 (72) |
| Any prior immunomodulator | 42 (64) |
aAccording to the Montreal classification12